sales@reportocean.com (Bussiness Sales)
+18882123539 (Us - Toll Free)
+919997112116 (Rest Of World)
Global Human Growth Hormone Market Size Study, by Application, by Route of Administration, by Distribution Channel and Regional Forecasts 2024-2032

Global Human Growth Hormone Market Size Study, by Application, by...

Home / Categories / Healthcare
Global Human Growth Hormone Market Size Study, by Application, by Route of Administration, by Distribution Channel and Regional Forecasts 2024-2032
Global Human Growth Hormone Market...
Report Code
RO1/103/3258

Publish Date
06/Nov/2024

Pages
200
PRICE
$ 1800/-
This is a single user license, allowing one specific user access to the product. The product is a PDF.
$ 2350/-
This is a 1-5 user license, allowing up to five users have access to the product. The product is a PDF.
$ 2850/-
This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..
The Global Human Growth Hormone (Hgh) market, valued at USD 5.39 Billion in 2023, is expected. This growth is projected to occur at a compound annual growth rate (CAGR) of 9.0% from 2021 to 2030. Human growth hormone, or somatotropin, is a critical peptide hormone produced by the pituitary gland, essential for regulating various physiological processes, including cell growth, regeneration, metabolism, and overall human development. The hormone's role extends beyond growth, aiding in muscle strength, bone density, and recovery from injuries.

The increasing prevalence of growth hormone deficiencies and genetic disorders such as Prader-Willi syndrome and Turner syndrome is driving the demand for hGH therapies. Turner syndrome, a condition characterized by the partial or complete loss of the X chromosome in females, is notably common, affecting approximately 1 in 2,500 live female births. The rising awareness of the importance of hGH in managing these conditions, coupled with advancements in hormone therapies that offer reduced side effects and longer treatment durations, is further propelling market growth.

The ongoing COVID-19 pandemic has highlighted the significance of managing growth hormone deficiencies, particularly in vulnerable populations such as those with Prader-Willi syndrome and Turner syndrome. The pandemic's impact on global healthcare systems has posed challenges, including delays in diagnosis and treatment. However, the market is expected to recover as healthcare services resume and awareness continues to grow regarding the importance of hGH treatments in managing associated health risks.

The market segmentation reveals that the Turner syndrome application segment held a dominant position in 2020 and is expected to maintain its lead throughout the forecast period. This dominance is attributed to the increasing incidence of Turner syndrome worldwide. In terms of the route of administration, the subcutaneous segment is expected to continue leading the market due to its higher efficacy in hormone absorption compared to other methods. Additionally, the hospital pharmacy segment remains the primary distribution channel, given its accessibility and the availability of recombinant human growth hormones.

The key regions considered in the study include Asia Pacific, North America, Europe, Latin America, and the Middle East and Africa. North America dominated the global human growth hormone market in 2020, driven by factors such as an aging population, the presence of major market players, and ongoing research into innovative hormone therapies. Asia-Pacific is anticipated to witness the highest growth rate during the forecast period, supported by population growth, increasing healthcare awareness, and improvements in healthcare infrastructure.

Major market players included in this report are:
Merck & Co.
Novo Nordisk
Eli Lilly & Company
Pfizer Inc.
Novartis AG
Teva Pharmaceutical Industries
Anhui Anke Biotechnology (Group) Co., Ltd.
Roche
Ipsen
Ferring BV
Anhui Anke Biotechnology Group Co., Ltd.
BioPartners GmbH
GeneScience Pharmaceuticals Co., Ltd.
LG Chem
Ascendis Pharma A/S
The detailed segments and sub-segment of the market are explained below:
By Application:
Growth Hormone Deficiency
Prader-Willi Syndrome
Turner Syndrome
Small for Gestational Age (SGA)
Others
By Route of Administration:
Oral
Intravenous
Intramuscular
Subcutaneous
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Region:
North America
U.S.
Canada
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East and Africa
Saudi Arabia
South Africa
Rest of Middle East and Africa
Years considered for the study are as follows:
Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with country-level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand-side and supply-side analysis of the market.

OUR CLIENTS

500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
+18882123539
sales@reportocean.com